Globenewswire·2025-11-10 21:09Core Viewpoint - LAVA Therapeutics N.V. is urging its shareholders to tender their shares in the ongoing acquisition offer from XOMA Royalty Corporation before the expiration deadline of November 12, 2025, to avoid potential risks associated with the failure of the transaction [1][3][12]. Group 1: Transaction Details - On August 4, 2025, LAVA and XOMA entered into a share purchase agreement, with XOMA extending its offer to purchase all outstanding common shares of LAVA until November 12, 2025 [2]. - The LAVA Board unanimously recommends that shareholders tender their shares to ensure the completion of the offer [3]. Group 2: Risks of Non-Completion - If the requisite percentage of shares is not tendered, the offer cannot be completed, which may lead to significant risks for shareholders, including potential liquidation and dissolution of LAVA [3][6]. - In the event of non-completion, LAVA's share price may decline, particularly if the current market price reflects expectations of the offer being completed [6]. Group 3: Share Tendering Process - Shareholders holding LAVA shares through brokers are advised to instruct their brokers to tender their shares promptly to meet processing deadlines [4][5]. - Those who have previously tendered their shares do not need to take any further action due to the extension of the offer [8]. Group 4: Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships including Johnson & Johnson and Pfizer [9].